OOIR: Observatory of International Research

Papers

(The H4-Index of Cellular & Molecular Immunology is 69. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Functional exhaustion of antiviral lymphocytes in COVID-19 patients	1272
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine	1258
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications	1084
Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients	721
Necroptosis, pyroptosis and apoptosis: an intricate game of cell death	706
NLRP3 inflammasome activation and cell death	456
Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies	388
Tumor-infiltrating lymphocytes in the immunotherapy era	385
The ORF3a protein of SARS-CoV-2 induces apoptosis in cells	372
Serum IgA, IgM, and IgG responses in COVID-19	361
Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor	305
An update on the regulatory mechanisms of NLRP3 inflammasome activation	287
COVID-19: a new challenge for human beings	283
Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities	282
SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70	270
A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity	256
Neutrophil chemoattractant receptors in health and disease: double-edged swords	239
Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients	192
Macrophages and the maintenance of homeostasis	177
Cancer immunotherapy with γδ T cells: many paths ahead of us	175
Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses	173
Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors	171
The blood–brain barrier in systemic infection and inflammation	171
Gut microbiome, liver immunology, and liver diseases	166
Neutrophils in chronic inflammatory diseases	165

Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases	165
Increased immune escape of the new SARS-CoV-2 variant of concern Omicron	164
The function and clinical application of extracellular vesicles in innate immune regulation	161
Unique immunological profile in patients with COVID-19	159
Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients	156
Control of lymphocyte functions by gut microbiota-derived short-chain fatty acids	155
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells	152
Dendritic cell migration in inflammation and immunity	147
Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV	143
New insights into the evasion of host innate immunity by Mycobacterium tuberculosis	141
SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated innate antiviral response	133
SARS-CoV-2-specific T cells in infection and vaccination	121
Metabolism of tissue macrophages in homeostasis and pathology	114
Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer	114
Manganese salts function as potent adjuvants	104
Pathological and molecular examinations of postmortem testis biopsies reveal SARS-CoV-2 infection in the testis and spermatogenesis damage in COVID-19 patients	102
High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients	101
Ubiquitination of SARS-CoV-2 ORF7a promotes antagonism of interferon response	100
Activation or exhaustion of CD8+ T cells in patients with COVID-19	100
Tumor-associated myeloid cells: diversity and therapeutic targeting	99
The cutting-edge progress of immune-checkpoint blockade in lung cancer	97
SARS-CoV-2 ORF10 suppresses the antiviral innate immune response by degrading MAVS through mitophagy	96
SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation	93
Immunological mechanisms and therapeutic targets of fatty liver diseases	90
Tertiary lymphoid structures in cancer – considerations for patient prognosis	90
Physiology of gangliosides and the role of antiganglioside antibodies in human diseases	90
Neutralizing antibodies for the prevention and treatment of COVID-19	89
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors	89
Shared and distinct roles of T peripheral helper and T follicular helper cells in human diseases	89
Dendritic cells in cancer immunology	89
ACOD1 in immunometabolism and disease	85
Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods	83
Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells	81
Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseases	81
Human immunology and immunotherapy: main achievements and challenges	80
Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies	80
Phages and their potential to modulate the microbiome and immunity	79
New insights into the cell- and tissue-specificity of glucocorticoid actions	78
Neutrophils in liver diseases: pathogenesis and therapeutic targets	77
Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics	77
Pyroptotic macrophages stimulate the SARS-CoV-2-associated cytokine storm	73
Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection	73
Expansion of atypical memory B cells is a prominent feature of COVID-19	72
Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment	70
Ligand recognition by the γδ TCR and discrimination between homeostasis and stress conditions	69